Jeff Yass’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$566K Buy
185,000
+50,800
+38% +$169K ﹤0.01% 9416
2026
Q2
$495K Sell
134,200
-52,800
-28% -$175K ﹤0.01% 9946
2026
Q1
$651K Buy
187,000
+121,500
+185% +$462K ﹤0.01% 8986
2025
Q4
$227K Sell
65,500
-334,000
-84% -$1.49M ﹤0.01% 10589
2025
Q3
$2.21M Buy
399,500
+314,300
+369% +$1.28M ﹤0.01% 5560
2025
Q2
$210K Buy
+85,200
New +$131K ﹤0.01% 11109
2024
Q4
– Sell
-233,800
Closed -$905K – 12998
2024
Q3
$905K Buy
233,800
+180,800
+341% +$838K ﹤0.01% 7018
2024
Q2
$272K Buy
+53,000
New +$321K ﹤0.01% 9664

Other funds holding PRME

Jeff Yass's PRME Position: Q3 2026 in Review

Jeff Yass increased its Prime Medicine (PRME) stake by 6.3% in Q3 2026, buying an estimated $135K and bringing the position to 689,157 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #6147.

Jeff Yass first reported a position in PRME in Q2 2023 and has held it in 13 quarters since. The position peaked at $4.08M in Q4 2025. 185 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Jeff Yass held 689,157 shares of Prime Medicine worth $2.11M as of Q3 2026.
  • Jeff Yass bought 40,678 Prime Medicine shares in Q3 2026, an estimated $135K.
  • Prime Medicine made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #6147 holding.
  • Jeff Yass first reported a position in Prime Medicine in Q2 2023 and has held it in 13 quarters since.
  • Jeff Yass's Prime Medicine position peaked at $4.08M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.